1,077 filings
6-K
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
S-8 POS
SNY
Sanofi
15 Mar 24
Registration of securities for employees (post-effective amendment)
8:40am
6-K
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
IRAN
SNY
Sanofi
23 Feb 24
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
2:02pm
6-K
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
6-K
9g3n6tc ru5ia4gf7cd
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
ahcncjide0szxfrvy
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
mvgoomd9ktdblw07ag
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
7nteqpj4cqrljbuypqx
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
emk1ckuq3qr
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
3wcwdcc
20 Dec 23
Current report (foreign)
10:39am
F-6EF
gt2tmmppy7 5nh4diu
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
org vueymumywry1
1 Dec 23
Current report (foreign)
12:19pm
6-K
9i9065jzcehyn
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
2v0qds15c16
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
6c6kb8t1vuo
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
d54eey2gj8pxpp
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
y87z9657 weyska
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
ed6sf853ly452hl4y3
27 Sep 23
Current report (foreign)
6:06am
6-K
24pkl6
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am